1. Home
  2. CNXN vs DFTX Comparison

CNXN vs DFTX Comparison

Compare CNXN & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNXN

PC Connection Inc.

HOLD

Current Price

$65.04

Market Cap

1.6B

ML Signal

HOLD

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$20.49

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CNXN
DFTX
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
CNXN
DFTX
Price
$65.04
$20.49
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$38.50
AVG Volume (30 Days)
61.9K
1.7M
Earning Date
04-29-2026
05-04-2026
Dividend Yield
1.26%
N/A
EPS Growth
N/A
N/A
EPS
0.68
N/A
Revenue
N/A
N/A
Revenue This Year
$6.24
N/A
Revenue Next Year
$4.39
N/A
P/E Ratio
$94.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.97
$14.62
52 Week High
$69.30
$26.25

Technical Indicators

Market Signals
Indicator
CNXN
DFTX
Relative Strength Index (RSI) 56.24 43.61
Support Level $56.30 $20.27
Resistance Level $67.55 $26.25
Average True Range (ATR) 2.01 1.03
MACD -0.19 -0.28
Stochastic Oscillator 61.05 6.74

Price Performance

Historical Comparison
CNXN
DFTX

About CNXN PC Connection Inc.

PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).

Share on Social Networks: